Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2022 / Aug / One Step Back
Research & Innovations

One Step Back

Recent allegations of image manipulation in a major Alzheimer’s disease paper reaffirm the importance of research integrity

By Geoffrey Potjewyd 8/5/2022 3 min read

Share

The latest scientific development to generate lively conversation in my friend group is the allegations of research fraud in a series of Alzheimer’s disease-related research. This development has had us lamenting the falsification of medical research – and talking about the cost of this kind of activity. Coming from a previous life in a dementia research lab, the news has prompted speculation on the impact it will have on Alzheimer’s research and beyond… even in ophthalmology.

If you haven’t heard, allegations of altering research images were made against Sylvain Lesné at the University of Minnesota. These data manipulations were found in 20 papers, including a Nature paper from 2006 (100 years on from Alois Alzheimer’s original description) in which a specific form of amyloid-β (Aβ), Aβ*56, was identified as a toxic oligomer in Alzheimer’s disease. Aβ protein deposits are an archetypal hallmark of the disease and have been pursued by many as a target for therapeutic intervention. The falsified data has not only harmed Alzheimer’s research since its publication, but could also foster further mistrust in the scientific and medical communities at a time when public trust in science is needed more than ever.

Consider sustainability. This falsification sent many researchers down the wrong path (most couldn’t replicate Lesné’s findings before the recent revelation came to light), draining researchers’ time and money (mainly from public and charity sources) and consuming physical resources such as plastic that will increase the size of scientific investigation’s already massive waste footprint.

It’s almost certain that there are multiple research papers published with fraudulent data that are still running free. There is even a site dedicated to people posting suspected manipulations of data (1). Hopefully, such instances are rare in ophthalmic circles, but this incident reminds us all of the importance of scientific integrity. Its widespread impact harms patients, clinicians, and researchers alike.

Despite the uproar, discussion, and intrigue on social media and online, hopefully research into the toxicity of oligomeric Aβ survives unscathed. Although this paper’s claims must now be disregarded, many Alzheimer’s researchers have stepped forward to highlight the good work being done on oligomeric Aβ and other Aβ species. In addition, some in the field have questioned the importance of pursuing this avenue and don’t support the hypothesis that this one species is a focal point of the disease. Such is the nature of complex disease – and the reason the mystery of Alzheimer’s disease, over a century old, has yet to be resolved.

The net of doubt cast by fraudulent research and medical practice is not exclusive to any one field – but, hopefully, the allegations will not erode trust in ophthalmology. From a financial and humanitarian perspective, we can’t afford to waste resources following false leads or undoing the damage done by irresponsible researchers. Although it may seem like common sense, it is vital to emphasize ethical research and clinical practices at every opportunity.

References

  1. PubPeer (2022). Available at: https://pubpeer.com.

About the Author(s)

Geoffrey Potjewyd

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

More Articles by Geoffrey Potjewyd

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: